What does Bifidobacterium lactis HN019 do?

A probiotic strain widely used in supplements, but recent large trials show it may not outperform placebo for constipation.

Is Bifidobacterium lactis HN019 safe?

Two large, rigorous randomized controlled trials (one in France, one in China) found HN019 did NOT outperform placebo for functional constipation — a primary marketed use.

Bifidobacterium lactis HN019 - Science-Based Research

What the Science Says

Bifidobacterium lactis HN019 is a probiotic bacterium — a live microorganism added to supplements and infant formulas to support gut health. It has been studied primarily for relieving functional constipation and supporting immune function. When used as part of a multi-strain probiotic blend, it has shown some potential benefits for reducing fever duration in children with respiratory infections and improving cholesterol and blood sugar markers in hypertensive women, though it is difficult to isolate HN019's specific contribution in those combination studies.

What It Doesn't Do

Won't reliably relieve constipation — two large, well-designed clinical trials found it performed no better than placebo. Not proven to improve bowel movement frequency on its own. No solid evidence it aids weight loss or improves body composition. Don't expect it to fix gut problems overnight or replace dietary fiber and hydration.

Evidence-Based Benefits

Bifidobacterium lactis HN019 is a probiotic bacterium — a live microorganism added to supplements and infant formulas to support gut health. It has been studied primarily for relieving functional constipation and supporting immune function. When used as part of a multi-strain probiotic blend, it has shown some potential benefits for reducing fever duration in children with respiratory infections and improving cholesterol and blood sugar markers in hypertensive women, though it is difficult to isolate HN019's specific contribution in those combination studies.

Weak Evidence

Effective at: No established dose based on provided studies — trials used ~4.69–9 billion CFU/day without consistent benefit

Source: auto-research

Absorption & Bioavailability

Unknown — probiotic survival through the gut is strain-dependent and not directly measured in the provided studies. Viability at end of study was lower than starting dose (7.0 × 10⁹ dropping to 4.69 × 10⁹ CFU/day), suggesting some degradation over time.

Red Flags to Watch For

Two large, rigorous randomized controlled trials (one in France, one in China) found HN019 did NOT outperform placebo for functional constipation — a primary marketed use.
Most positive findings come from multi-strain probiotic blends, making it impossible to credit HN019 specifically.
Widely added to infant formula in China despite acknowledged insufficient scientific evidence on feeding effects.
Products containing this strain vary widely in CFU dose and formulation — label claims may not reflect what was tested in clinical trials.

Research Sources

PubMed
NIH DSLD